Does Adding Lutetium-177 Lu-PSMA-617 to Enzalutamide in mCRPC Improve OS, QOL?

Background: Both lutetium-177 [ 177 Lu]Lu-prostate-specific membrane antigen-617 (Lu-PSMA-617) and androgen receptor inhibitors improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). PSMA is a transmembrane receptor involved in the PI3K–mTOR growth pathway, which increases expression during androgen blockade in patients with mCRPC. This pathway compensates for the androgen blockade. The hypothesis was that by targeting both androgen signaling and PSMA receptors, the anticancer activity in mCRPC would be enhanced. Objective: To report on overall survival (OS) and health-related quality of life (HRQOL) when [ 177 Lu]Lu-PSMA-617 is added to enzalutamide. Design: Open-label, multicenter, randomized phase 2 trial. Participants: Patients had mCRPC not previously treated with androgen receptor antagonist or docetaxel with rising prostate-specific antigen (PSA) of at least >5 ng/mL. Prior treatment for hormone-sensitive disease with docetaxel or abirate more...